Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026

2 weeks ago 10

Jonathan Ponciano, The Motley Fool

Fri, March 20, 2026 astatine 11:27 AM CDT 3 min read

On February 17, 2026, Boone Capital Management sold retired its full Cogent Biosciences (NASDAQ:COGT) stake, liquidating 945,042 shares antecedently worthy $13.57 million.

According to an SEC filing dated February 17, 2026, Boone Capital Management sold its full holding of 945,042 shares successful Cogent Biosciences during the 4th quarter. The quarter-end presumption worth dropped by $13.57 million, reflecting the afloat liquidation.

Top 5 holdings aft the filing:
- NYSE: MDT: $41.19 cardinal (12.9% of AUM)
- NASDAQ: MIRM: $33.27 cardinal (10.4% of AUM)
- NASDAQ: IONS: $33.05 cardinal (10.4% of AUM)
- NYSE: CI: $26.55 cardinal (8.3% of AUM)
- NASDAQ: BMRN: $24.48 cardinal (7.7% of AUM)
As of Friday, shares of Cogent Biosciences were priced astatine $34.40, up a staggering 372% implicit the past twelvemonth and vastly outperforming the S&P 500’s astir 16% summation successful the aforesaid period.

Metric

Value

Price (as of Friday)	$34.40
Market Capitalization	$5.6 billion
Net Income (TTM)	($328.94 million)

Cogent Biosciences develops precision therapies targeting genetically defined diseases, with a pb merchandise campaigner (CGT9486) focused connected treating systemic mastocytosis and precocious gastrointestinal stromal tumors.
The institution operates a biotechnology R&D model, generating worth done clinical-stage cause improvement and strategical licensing agreements, specified arsenic its concern with Plexxikon Inc. for bezuclastinib.
It targets patients with uncommon familial mutations, peculiarly those affected by KIT-driven cancers and systemic mastocytosis, serving the planetary biopharmaceutical and healthcare markets.

Cogent Biosciences is simply a clinical-stage biotechnology institution specializing successful the improvement of targeted therapies for genetically defined diseases. The institution leverages precision medicine and a focused pipeline to code important unmet aesculapian needs successful oncology and uncommon illness markets. Its strategy centers connected advancing innovative kinase inhibitors, supported by strategical collaborations and a committedness to technological excellence.

Locking successful gains amid a staggering tally is often simply astir discipline, but what stands retired present is wherever superior shifted successful the aforesaid period.

To beryllium clear, Cogent is not broken. It is arguably successful its strongest presumption yet, with astir $900 cardinal successful currency arsenic of December 31 and a wide way toward imaginable commercialization, including aggregate NDA filings and a imaginable motorboat aboriginal this year. But that spot is besides the point. Much of the near-term upside whitethorn already beryllium reflected aft specified a monolithic move, and shares are down astir 3% since the extremity of past quarter.

By contrast, the newer presumption successful TYRA is up much than 40% this year, though it inactive sits earlier successful its objective and valuation curve. Compared to the fund’s halfway holdings, which skew toward much established biotech names, this displacement looks similar a deliberate determination backmost into higher-upside, earlier-stage risk.

Read Entire Article